论文部分内容阅读
目的了解甘露聚糖肽注射液不良反应的特点和安全因素,为临床安全用药提供文献依据。方法检索2002年至2016年国内报道的甘露聚糖肽注射液的不良反应报道,建立数据库进行分项统计和分析,探讨药物不良反应的发生与各因素之间的关系。结果甘露聚糖肽注射液的不良反应涉及人体多个系统,其中以呼吸系统最多,主要表现为胸闷、呼吸困难。甘露聚糖肽注射液的不良反应发生因素主要有药物因素、临床用法用量、滴速及患者本身的因素等。结论甘露聚糖肽注射液可引起严重不良反应,应当关注其风险因素,加强监管,防止不良反应的发生。
Objective To understand the characteristics and safety factors of adverse reactions of mannan glycopeptide injection and provide references for clinical safety medication. Methods The reports of adverse reactions of mannan glycopeptide injection reported in China from 2002 to 2016 were retrieved. The database was established for statistical analysis and analysis to explore the relationship between the occurrence of adverse drug reactions and various factors. Results Mannitol peptide injection adverse reactions involving the human body more than one system, of which the respiratory system most, mainly for chest tightness, difficulty breathing. Mannan peptide injection adverse reactions occur mainly drug factors, clinical dosage, drip rate and the patient’s own factors. Conclusion Mannan peptide injection can cause serious adverse reactions, should pay attention to its risk factors, strengthen supervision, prevent the occurrence of adverse reactions.